X-Linked Agammaglobulinemia: Chasing a Higher Trough or a Damaged Airway
A fifteen-year-old with X-linked agammaglobulinemia keeps getting sinus infections at a trough that used to protect him. The debate is whether the answer is more immunoglobulin, or whether his airway itself has become the problem an IgG number can't fix.
Theo M. plays second base for his high school's junior varsity team and has missed more practices this season than any of his three years playing, all to sinus infections that no longer clear on the usual course of antibiotics before the next one starts. He was diagnosed with X-linked agammaglobulinemia at fourteen months old after his older cousin's own diagnosis prompted genetic testing across the family, and has been on monthly intravenous immunoglobulin since — stable enough through elementary and middle school that his parents had largely stopped thinking about it day to day. He has no history of pneumonia requiring hospitalization and no known drug allergies, and his growth and development have tracked normally throughout.
His current dosing, 400 mg/kg every four weeks, produces a trough of roughly 650 mg/dL — not a low number by older standards, but Orange et al., 2010, pooling seventeen studies and 676 patients, found pneumonia incidence declining 27% with every additional 100 mg/dL of trough, with a five-fold difference in pneumonia rate between a 500 mg/dL trough and a 1000 mg/dL one. That data argues his current level may simply be too low for a teenager whose infections have started accelerating rather than settling with age, the pattern most XLA patients show as maternal-antibody-independent immunity otherwise would have matured. But five sinus infections in eight months, three of them with productive cough lasting weeks after the sinus symptoms cleared, is also exactly the pattern that precedes a bronchiectasis diagnosis in longstanding antibody deficiency — a structural change that traps bacteria in damaged airway segments no circulating IgG level, however high, can dislodge. He has never had a chest CT since diagnosis, since chest X-rays through age twelve were consistently unremarkable and nobody had reason yet to look more closely.
A number to raise, or an airway to image first
Orange and colleagues pooled seventeen studies and found pneumonia incidence falling 27% for every 100 mg/dL rise in trough, with a five-fold difference between a 500 and a 1000 mg/dL trough. His current trough sits around 650. I want to raise his dose and re-check in three months — that's a real, modifiable lever we haven't fully used yet.
That data is real, but it describes pneumonia risk in a general antibody-deficient population, not specifically what happens once bronchiectasis has already set in. Three infections this year left him with weeks of productive cough after the sinus symptoms resolved — that's not a pattern I'd expect purely from a trough that's merely suboptimal. I'd want a chest CT before assuming more immunoglobulin is the whole answer.
A five-fold pneumonia-risk difference between troughs is a real number, but Orange pooled all comers with antibody deficiency on replacement and never stratified anyone by airway structure. It tells us what a higher trough buys the average patient in a mixed population. It cannot tell us what it buys a boy whose airways are already damaged, because that question was never asked of the data.
We don't have to choose blind. A high-resolution CT this week tells us which problem we're actually treating, and it doesn't delay anything — raise his dose now while we wait for the scan, since there's no real downside to doing both. If the CT is clean, the trough increase is the whole story and we watch his response over the next two cycles. If it shows bronchiectasis, the dose increase stays in place for the antibody-deficiency side of the equation, but airway clearance and possibly prophylactic azithromycin become the actual answer to the recurring cough.
His IVIG dose was raised this visit rather than waiting on imaging, and the CT was scheduled for the following week. The scan showed early cylindrical bronchiectasis limited to the right middle lobe — present, but not yet the diffuse disease that would make antibody dosing largely beside the point.
Both the higher trough and airway clearance were kept in place going forward, agreed by all three specifically because the finding was early rather than extensive. Not agreed: whether the higher dose should have waited for the CT result in the first place — the pulmonologist would have preferred confirming the diagnosis before committing to a more expensive, higher-volume infusion regimen, while the immunologist held that the trough data justified the increase regardless of what the scan eventually showed.